

# John N Galgiani

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6167434/john-n-galgiani-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138  
papers

7,057  
citations

44  
h-index

82  
g-index

147  
ext. papers

8,058  
ext. citations

6.1  
avg. IF

5.5  
L-index

#	Paper	IF	Citations
138	Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac032	1	
137	Mouse Model of a Human STAT4 Point Mutation That Predisposes to Disseminated Coccidiomycosis.. <i>ImmunoHorizons</i> , <b>2022</b> , 6, 130-143	2.7	1
136	The WOPR family protein Ryp1 is a key regulator of gene expression, development, and virulence in the thermally dimorphic fungal pathogen <i>Coccidioides posadasii</i> .. <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1009832	7.6	0
135	Cross-Sectional Study of Clinical Predictors of Coccidioidomycosis, Arizona, USA. <i>Emerging Infectious Diseases</i> , <b>2022</b> , 28, 1091-1100	10.2	2
134	Clinician Practice Patterns That Result in the Diagnosis of Coccidioidomycosis Before or During Hospitalization. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1587-e1593	11.6	5
133	Vaccine Protection of Mice With Primary Immunodeficiencies Against Disseminated Coccidioidomycosis.. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 790488	5.9	0
132	TNF $\beta$ Blockade Inhibits Both Initial and Continued Control of Pulmonary .. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 796114	5.9	
131	FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	1
130	Epis1 vaccine protects dogs against experimentally induced coccidioidomycosis. <i>Vaccine</i> , <b>2021</b> , 39, 6894-6901	6.9	1
129	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). <i>Contemporary Clinical Trials Communications</i> , <b>2021</b> , 24, 100851	1.8	1
128	Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa623	1	6
127	Natural History of Disseminated Coccidioidomycosis: Examination of the Veterans Affairs-Armed Forces Database. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e3814-e3819	11.6	6
126	Comparison of a Novel Rapid Lateral Flow Assay to Enzyme Immunoassay Results for Early Diagnosis of Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2746-e2753	11.6	12
125	A quantitative enzyme-linked immunoassay (ELISA) to approximate complement-fixing antibody titers in serum from patients with coccidioidomycosis. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2021</b> , 99, 115198	2.9	4
124	A Chronic Murine Disease Model of Coccidioidomycosis Using <i>Coccidioides posadasii</i> , Strain 1038. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 166-173	7	6
123	Demonstration of $\beta$ -Dimethyldithiocarbamate as a Copper-Dependent Antibiotic against Multiple Upper Respiratory Tract Pathogens. <i>Microbiology Spectrum</i> , <b>2021</b> , 9, e0077821	8.9	2
122	42. Common Population Variants Cause Susceptibility to Disseminated Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S22-S23	1	2

121	A Pilot Study of Valley Fever Tweets. <i>Infection Control and Hospital Epidemiology</i> , <b>2020</b> , 41, s101-s101	2	
120	Differential Thermotolerance Adaptation between Species of. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2020</b> , 6,	5.6	5
119	Treatment for Early, Uncomplicated Coccidioidomycosis: What Is Success?. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 2008-2012	11.6	12
118	Delays in Coccidioidomycosis Diagnosis and Relationship to Healthcare Utilization, Phoenix, Arizona, USA. <i>Emerging Infectious Diseases</i> , <b>2019</b> , 25, 1742-1744	10.2	6
117	The Rise of : Forces Against the Dust Devil Unleashed. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2188	8.4	21
116	Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA. <i>Emerging Infectious Diseases</i> , <b>2019</b> , 25, 1745-1747	10.2	12
115	Characterizing in vitro spherule morphogenesis of multiple strains of both species of Coccidioides. <i>Medical Mycology</i> , <b>2019</b> , 57, 478-488	3.9	13
114	Early Events in Coccidioidomycosis. <i>Clinical Microbiology Reviews</i> , <b>2019</b> , 33,	34	14
113	Delays in Coccidioidomycosis Diagnosis and Relationship to Healthcare Utilization, Phoenix, Arizona, USA1. <i>Emerging Infectious Diseases</i> , <b>2019</b> , 25, 1742-1744	10.2	8
112	Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA. <i>Emerging Infectious Diseases</i> , <b>2019</b> , 25, 1745-1747	10.2	5
111	Coccidioidal Meningitis in New York Traced to Texas by Fungal Genomic Analysis. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1060-1062	11.6	6
110	2888. STAT4 Mutation in Three Generations with Disseminated Coccidioidomycosis (DCM) also Exhibits Increased Susceptibility to Coccidioidal Infection in Transfected Mice. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S77-S78	1	3
109	1718. The Natural History of Chronic Pulmonary Coccidioidomycosis in the Pre-Antifungal Era. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S630-S630	1	78
108	1732. A Canine Target Species Challenge Model to Evaluate Efficacy of a Coccidioidomycosis Vaccine. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S634-S635	1	2
107	2598. Macrophage Migration Inhibitory Factor May Contribute to Disseminated Coccidioidomycosis Susceptibility. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S903-S903	1	78
106	Population Structure and Genetic Diversity among Isolates of in Venezuela and Surrounding Regions. <i>MBio</i> , <b>2019</b> , 10,	7.8	8
105	Viable spores of <i>Coccidioides posadasii</i> Δ <i>eps1</i> are required for vaccination and provide long lasting immunity. <i>Vaccine</i> , <b>2018</b> , 36, 3375-3380	4.1	12
104	Glucan-Chitin Particles Enhance Th17 Response and Improve Protective Efficacy of a Multivalent Antigen (rCpa1) against Pulmonary <i>Coccidioides posadasii</i> Infection. <i>Infection and Immunity</i> , <b>2018</b> , 86,	3.7	22

103	386. A Reexamination of Disseminated Coccidioidomycosis: The Natural History in the Pre-Antifungal Era. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S149-S150	1	1
102	Oxygen Consumption Deficits in Patients With Residual Fatigue After Primary Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx136	1	
101	Approach to Management of Coccidioidomycosis in Patients Receiving Inhibitors of Tumor Necrosis Factor- $\alpha$ . <i>Infectious Diseases in Clinical Practice</i> , <b>2017</b> , 25, 184-192	0.2	3
100	Top Questions in the Diagnosis and Treatment of Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx197	1	8
99	Risk Factors for Disseminated Coccidioidomycosis, United States. <i>Emerging Infectious Diseases</i> , <b>2017</b> , 23,	10.2	65
98	Natural History of Non-CNS Disseminated Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S77-S77	1	78
97	2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, e112-46	11.6	270
96	Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 717-22	11.6	53
95	Effect of Geography on the Analysis of Coccidioidomycosis-Associated Deaths, United States. <i>Emerging Infectious Diseases</i> , <b>2016</b> , 22, 1821-3	10.2	8
94	A <i>Coccidioides posadasii</i> CPS1 Deletion Mutant Is Avirulent and Protects Mice from Lethal Infection. <i>Infection and Immunity</i> , <b>2016</b> , 84, 3007-16	3.7	29
93	Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7249-54	5.9	37
92	The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 787-91	11.6	39
91	A paradigm for the evaluation and management of spinal coccidioidomycosis. <i>Surgical Neurology International</i> , <b>2015</b> , 6, 107	1	11
90	Coccidioidomycosis ( <i>Coccidioides</i> Species) <b>2015</b> , 2974-2984.e3		4
89	Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 1949-54	7	43
88	Application of immunosignatures for diagnosis of valley fever. <i>Vaccine Journal</i> , <b>2014</b> , 21, 1169-77		15
87	Regional dust storm modeling for health services: The case of valley fever. <i>Aeolian Research</i> , <b>2014</b> , 14, 53-73	3.9	58
86	Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 131, 1624-34	11.5	162

85	Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. <i>Clinical Microbiology Reviews</i> , <b>2013</b> , 26, 505-25	34	175
84	Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs. <i>Medical Mycology</i> , <b>2013</b> , 51, 747-54	3.9	32
83	Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1903-9	4.7	40
82	Physical characterization of the "immunosignaturing effect". <i>Molecular and Cellular Proteomics</i> , <b>2012</b> , 11, M111.011593	7.6	40
81	Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus. <i>Virulence</i> , <b>2012</b> , 3, 329-38	4.7	11
80	The public health impact of coccidioidomycosis in Arizona and California. <i>International Journal of Environmental Research and Public Health</i> , <b>2011</b> , 8, 1150-73	4.6	92
79	Interleukin-12 receptor $\alpha$ 1 deficiency predisposing to disseminated Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, e99-e102	11.6	68
78	An insight into the antifungal pipeline: selected new molecules and beyond. <i>Nature Reviews Drug Discovery</i> , <b>2010</b> , 9, 719-27	64.1	305
77	Coccidioidomycosis among scholarship athletes and other college students, Arizona, USA. <i>Emerging Infectious Diseases</i> , <b>2010</b> , 16, 321-3	10.2	12
76	Population genomic sequencing of Coccidioides fungi reveals recent hybridization and transposon control. <i>Genome Research</i> , <b>2010</b> , 20, 938-46	9.7	140
75	Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 172-8	11.6	57
74	Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, e62-5	11.6	87
73	Comparative genomic analyses of the human fungal pathogens Coccidioides and their relatives. <i>Genome Research</i> , <b>2009</b> , 19, 1722-31	9.7	229
72	Pharmacokinetics of nikkomycin Z after single rising oral doses. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2517-21	5.9	55
71	Mannose-binding lectin serum levels are low in persons with clinically active coccidioidomycosis. <i>Mycopathologia</i> , <b>2009</b> , 167, 173-80	2.9	9
70	Vaccine-induced cellular immune responses differ from innate responses in susceptible and resistant strains of mice infected with Coccidioides posadasii. <i>Infection and Immunity</i> , <b>2008</b> , 76, 5553-64	3.7	27
69	Vaccines to prevent systemic mycoses: holy grails meet translational realities. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 938-40	7	13
68	Nuclear labeling of Coccidioides posadasii with green fluorescent protein. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1111, 198-207	6.5	6

67	The application of proteomic techniques to fungal protein identification and quantification. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1111, 133-46	6.5	7
66	Coccidioidomycosis: changing perceptions and creating opportunities for its control. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1111, 1-18	6.5	23
65	Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques ( <i>Macaca fascicularis</i> ). <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1111, 290-300	6.5	17
64	Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 562-8	11.6	92
63	Efficacy of ambruticin analogs in a murine model of coccidioidomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 3467-9	5.9	18
62	Protein expression profiling of <i>Coccidioides posadasii</i> by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate. <i>Infection and Immunity</i> , <b>2006</b> , 74, 1865-72	3.7	36
61	Spherules derived from <i>Coccidioides posadasii</i> promote human dendritic cell maturation and activation. <i>Infection and Immunity</i> , <b>2006</b> , 74, 2415-22	3.7	26
60	<i>Coccidioides posadasii</i> contains single chitin synthase genes corresponding to classes I to VII. <i>Fungal Genetics and Biology</i> , <b>2006</b> , 43, 775-88	3.9	44
59	Improved protection of mice against lethal respiratory infection with <i>Coccidioides posadasii</i> using two recombinant antigens expressed as a single protein. <i>Vaccine</i> , <b>2006</b> , 24, 5904-11	4.1	44
58	Coccidioidomycosis as a common cause of community-acquired pneumonia. <i>Emerging Infectious Diseases</i> , <b>2006</b> , 12, 958-62	10.2	193
57	<i>Coccidioides posadasii</i> contains a single 1,3-beta-glucan synthase gene that appears to be essential for growth. <i>Eukaryotic Cell</i> , <b>2005</b> , 4, 111-20		33
56	Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1217-23	11.6	515
55	An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 1981-7	7	103
54	Program for the 45th coccidioidomycosis study group Tucson, Arizona, March 31, 2001. <i>Mycopathologia</i> , <b>2002</b> , 154, 1-13	2.9	
53	Protection of mice against <i>Coccidioides immitis</i> intranasal infection by vaccination with recombinant antigen 2/PRA. <i>Infection and Immunity</i> , <b>2002</b> , 70, 3287-9	3.7	48
52	Localization within a proline-rich antigen (Ag2/PRA) of protective antigenicity against infection with <i>Coccidioides immitis</i> in mice. <i>Infection and Immunity</i> , <b>2002</b> , 70, 3330-5	3.7	23
51	Molecular approaches to the study of <i>Coccidioides immitis</i> . <i>International Journal of Medical Microbiology</i> , <b>2002</b> , 292, 373-80	3.7	4
50	Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. <i>Annals of Internal Medicine</i> , <b>2000</b> , 133, 676-86	8	198

49	The <i>Cryptococcus neoformans</i> GeneDHA1 Encodes an Antigen That Elicits a Delayed-Type Hypersensitivity Reaction in Immune Mice. <i>Infection and Immunity</i> , <b>2000</b> , 68, 6196-6201	3.7	
48	Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. <i>Annals of Internal Medicine</i> , <b>1999</b> , 130, 293-300	8	125
47	Resistance to <i>Coccidioides immitis</i> in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. <i>Infection and Immunity</i> , <b>1999</b> , 67, 2935-40	3.7	44
46	Detecting serum antibodies to a purified recombinant proline-rich antigen of <i>Coccidioides immitis</i> in patients with coccidioidomycosis. <i>Clinical Infectious Diseases</i> , <b>1998</b> , 27, 1475-8	11.6	11
45	Evaluation of the proline-rich antigen of <i>Coccidioides immitis</i> as a vaccine candidate in mice. <i>Infection and Immunity</i> , <b>1998</b> , 66, 3519-22	3.7	47
44	Coccidioidomycosis: The Initial Pulmonary Infection and Beyond. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>1997</b> , 18, 235-247	3.9	8
43	Analysis of autoantibodies to T-cell receptors among HIV-infected individuals: epitope analysis and time course. <i>Clinical Immunology and Immunopathology</i> , <b>1997</b> , 82, 174-89		13
42	Cloning and sequence analysis of the cDNA for a protein from <i>Coccidioides immitis</i> with immunogenic potential. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 218, 485-9	3.4	37
41	The Role of Understaffing in Central Venous Catheter-Associated Bloodstream Infection. <i>Infection Control and Hospital Epidemiology</i> , <b>1996</b> , 17, 150-158	2	281
40	The role of understaffing in central venous catheter-associated bloodstream infections. <i>Infection Control and Hospital Epidemiology</i> , <b>1996</b> , 17, 150-8	2	178
39	Coccidioidomycosis among visitors to a <i>Coccidioides immitis</i> -endemic area: an outbreak in a military reserve unit. <i>Journal of Infectious Diseases</i> , <b>1995</b> , 171, 1672-5	7	46
38	Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , <b>1995</b> , 20, 1281-5	11.6	15
37	Differences in oxidant release by human polymorphonuclear leukocytes produced by stimulation with different phases of <i>Coccidioides immitis</i> . <i>Journal of Infectious Diseases</i> , <b>1995</b> , 172, 199-203	7	9
36	Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. <i>American Journal of Medicine</i> , <b>1995</b> , 98, 249-56	2.4	113
35	NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. <i>American Journal of Medicine</i> , <b>1994</b> , 97, 135-44	2.4	412
34	Comparative analysis of three antifungal susceptibility test methods against prospectively collected <i>Candida</i> species. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>1994</b> , 18, 89-94	2.9	4
33	Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>1994</b> , 20, 81-6	2.9	18
32	Cavitary coccidioidomycosis with fungus ball formation. Diagnosis by fiberoptic bronchoscopy with coexistence of hyphae and spherules. <i>Chest</i> , <b>1994</b> , 105, 412-6	5.3	25

31	Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. <i>American Journal of Medicine</i> , <b>1993</b> , 94, 235-40	2.4	148
30	Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. <i>Annals of Internal Medicine</i> , <b>1993</b> , 119, 28-35	8	139
29	Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection. <i>Transplantation</i> , <b>1993</b> , 55, 1422-4	1.8	35
28	Interaction of human peripheral blood mononuclear cells with <i>Coccidioides immitis</i> arthroconidia. <i>Cellular Immunology</i> , <b>1991</b> , 133, 253-62	4.4	12
27	Fluconazole, a new antifungal agent. <i>Annals of Internal Medicine</i> , <b>1990</b> , 113, 177-9	8	77
26	Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. <i>Medicine (United States)</i> , <b>1990</b> , 69, 384-91	1.8	135
25	Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. <i>American Journal of Medicine</i> , <b>1990</b> , 89, 282-90	2.4	151
24	Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. <i>American Journal of Medicine</i> , <b>1988</b> , 84, 603-10	2.4	86
23	Ketoconazole treatment of coccidioidal meningitis. <i>Annals of the New York Academy of Sciences</i> , <b>1988</b> , 544, 488-96	6.5	23
22	Extraction of serologic and delayed hypersensitivity antigens from spherules of <i>Coccidioides immitis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , <b>1988</b> , 11, 65-80	2.9	23
21	Coccidioidal peritonitis associated with continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , <b>1988</b> , 11, 512-4	7.4	14
20	Coccidioidomycosis during pregnancy. An analysis of ten cases among 47,120 pregnancies. <i>Chest</i> , <b>1988</b> , 94, 376-9	5.3	52
19	Development of dermal hypersensitivity to coccidioidal antigens associated with repeated skin testing. <i>The American Review of Respiratory Disease</i> , <b>1986</b> , 134, 1045-7		10
18	Susceptibility of <i>Candida albicans</i> to flucytosine when tested in different formulations of yeast nitrogen base broth. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>1986</b> , 5, 273-6	2.9	5
17	Studies of the effects of spherulin from <i>Coccidioides immitis</i> on human polymorphonuclear leukocytes. <i>Mycopathologia</i> , <b>1985</b> , 90, 107-11	2.9	3
16	Human polymorphonuclear-leukocyte inhibition of incorporation of chitin precursors into mycelia of <i>Coccidioides immitis</i> . <i>Journal of Infectious Diseases</i> , <b>1984</b> , 149, 404-12	7	28
15	Antigenemia in primary coccidioidomycosis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>1984</b> , 33, 645-9	3.2	24
14	Ketoconazole in the treatment of coccidioidomycosis. <i>Drugs</i> , <b>1983</b> , 26, 355-63	12.1	20



13	Amphotericin B and imidazole therapy for coccidioidal meningitis in children. <i>Pediatric Infectious Disease Journal</i> , <b>1983</b> , 2, 216-21	3.4	23
12	Clinical conference in pulmonary disease. Coccidioidomycosis. Clinical conference in pulmonary disease from the Tucson V.A. Medical Center and the University of Arizona. <i>Chest</i> , <b>1982</b> , 81, 488-92	5.3	3
11	Pertussis vaccine: An unnecessary renewal of anti-vaccine sentiment. <i>Infectious Diseases Newsletter (New York, N Y)</i> , <b>1982</b> , 1, 69-71		
10	Ketoconazole treatment of nonprimary coccidioidomycosis. Evaluation of 60 patients during three years of study. <i>American Journal of Medicine</i> , <b>1982</b> , 72, 681-7	2.4	41
9	Legionnaires disease following cardiac transplantation. <i>Chest</i> , <b>1981</b> , 79, 669-71	5.3	38
8	Gynecomastia with ketoconazole. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1981</b> , 19, 1073-4	5.9	126
7	Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole. <i>American Journal of Medicine</i> , <b>1978</b> , 65, 284-9	2.4	37
6	Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1978</b> , 13, 249-54	5.9	58
5	Paracoccidioidomycosis (South American blastomycosis): treatment with miconazole. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>1978</b> , 27, 801-7	3.2	20
4	Visceral fungal infections due to <i>Petrellidium boydii</i> ( <i>allescheria boydii</i> ). In vitro drug sensitivity studies. <i>American Journal of Medicine</i> , <b>1976</b> , 61, 632-40	2.4	131
3	Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1976</b> , 10, 721-8	5.9	143
2	How does genetics influence valley fever? research underway now to answer this question. <i>Southwest Journal of Pulmonary &amp; Critical Care</i> , 230-237	0.8	2
1	The WOPR family protein Ryp1 is a key regulator of gene expression, development, and virulence in the thermally dimorphic fungal pathogen <i>Coccidioides posadasii</i>		1